12 Oct 2023 Number of shares and voting rights of ADOCIA as of September 30th, 2023 Icon check
Jérémy Benattar – Investisseur.TV (FR)
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse (FR)
25 Sep 2023 ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses Icon check
18 Sep 2023 ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update Icon check
14 Sep 2023 Number of shares and voting rights of ADOCIA as of August 31st, 2023 Icon check
13 Sep 2023 ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or likely to be Issued to IPF Partners on Exercise of its Warrants Icon check
31 Aug 2023 ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners Icon check
30 Aug 2023 Number of shares and voting rights of ADOCIA as of July 31st, 2023 Icon check
31 Jul 2023 ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
27 Jul 2023 ADOCIA Announces the Availability of a Prospectus for its Capital Increase and Convertible Bond Issue Icon check
25 Jul 2023 ADOCIA announces Q2 2023 financial results and a €10 million financing operation Icon check
18 Jul 2023 ADOCIA confirms its eligibility for the PEA–PME Icon check
12 Jul 2023 Number of shares and voting rights of ADOCIA as of June 30th, 2023 Icon check
11 Jul 2023 EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772 Icon check
Webconference of July 6th, 2023
05 Jul 2023 ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing Icon check
23 Jun 2023 AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023
01 Jun 2023 Listing of ADOCIA shares suspended Icon check
15 May 2023 ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer Icon check
30 Apr 2023 Number of shares and voting rights of ADOCIA as of April 30th, 2023 Icon check
27 Apr 2023 ADOCIA Announces the Release of its Universal Registration Document for the Year 2022 Icon check
25 Apr 2023 ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities Icon check
20 Apr 2023 ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris Icon check
13 Apr 2023 Number of shares and voting rights of ADOCIA as of March 31st, 2023 Icon check
17 Mar 2023 Number of shares and voting rights of ADOCIA as of February 28th, 2023 Icon check
2022 Annual Results
15 Mar 2023 ADOCIA announces its annual results for 2022 and provides corporate and financial update Icon check
15 Feb 2023 Number of shares and voting rights of ADOCIA as of January 31st, 2023 Icon check
30 Jan 2023 ADOCIA – Letter to shareholders – January 2023 Icon check
30 Jan 2023 ADOCIA publishes its Letter to Shareholders Icon check
16 Jan 2023 Number of shares and voting rights of ADOCIA as of December 31st, 2022 Icon check
12 Jan 2023 ADOCIA Announces its financial calendar for 2023 Icon check
12 Jan 2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248. Icon check
29 Dec 2022 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao Icon check
21 Dec 2022 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Icon check
15 Dec 2022 Number of shares and voting rights of ADOCIA as of November 30th, 2022 Icon check
01 Dec 2022 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Icon check
16 Nov 2022 Number of shares and voting rights of ADOCIA as of October 31st, 2022 Icon check
25 Oct 2022 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Icon check
13 Oct 2022 Number of shares and voting rights of ADOCIA as of September 30th, 2022 Icon check
06 Oct 2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Icon check
03 Oct 2022 ADOCIA: Upcoming investor meetings Icon check
Investors Webinar of Sept 20th, 2022
19 Sep 2022 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Icon check
15 Sep 2022 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Icon check
14 Sep 2022 Number of shares and voting rights of ADOCIA as of August 31st, 2022 Icon check
07 Sep 2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Icon check
2022 AdoShell Islets Presentation
25 Aug 2022 Number of shares and voting rights of ADOCIA as of July 31st, 2022 Icon check
Join our mailing list. Subscribe